Age-Related Frailty
Initiated at Mayo Clinic, the human clinical trial will evaluate whether Elysium’s proprietary nicotinamide riboside (NR-E) can augment bone, skeletal muscle, and metabolic functions and structure in aging. The estimated primary study completion date is December 2024. ClinicalTrials.gov Identifier: NCT03818802